Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and nilotinib
2008-004384-19Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of imatinib and nilotinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by GIMEMA. Primary endpoint: Complete cytogenetic response at 12 months. Started Jul 2008; status: completed.
02
Drugs
imatinibnilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2008-004384-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004384-19.